Atropos Health co-authors study on semaglutide fracture risk
Study presented at ENDO2026 found semaglutide reduced fracture risk by 15% in type 2 diabetes patients.
See the latest news and media coverage for Atropos Health. We track all announcements, press releases, and industry mentions in real time, all in one place.
Real-world evidence generation platform and services
atroposhealth.comLast updated
In short: Atropos Health launched Alexandria, the world's largest evidence library, and expanded clinical AI partnerships and research.
Study presented at ENDO2026 found semaglutide reduced fracture risk by 15% in type 2 diabetes patients.
It combines predictive modeling and evidence generation to embed insights into the electronic health record.
Research uses Atropos Evidence™ Network data to evaluate liver safety, suggesting promising therapeutic approach. Authors include Atropos Health and Stanford experts.
The study analyzes real-world data from over 60 million patients to compare safety and efficacy of long-acting GCSFs in GI cancer chemotherapy patients.
OneMedNet Corporation (Nasdaq: ONMD) ("OneMedNet," the "Company," "we," "us," or "our"), a leading provider of regulatory decision-grade, AI-driven Real-World Data (RWD), today announced a strategic...
The Company is Also Forging Strategic Partnerships With Pharmaceutical Companies and Vertically Integrated Healthcare Companies to Drive Evidence Adoption in Oncology and other Specialty areas...
Atropos Health launches medical evidence library to support clinical decisions and integrate with systems used by Meta, Microsoft, and health systems.
Alexandria now includes 33M precision Evidence-Based Findings (pEBF™) growing to more than two billion studies in 2026, ...
Track Atropos Health and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Atropos Health and other trending companies.